Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
LAURION Reports Additional High-Grade Gold, Silver and Zinc Intersections at Ishkoday A-Zone/McLeod/CRK Zones, Confirming Structural Continuity Along the Mineralized Corridor
Alrajhi Medicine to Digitize its Healthcare Operations with Oracle to Foster Better Patient and Staff Experiences
Zscaler 2026 AI Threat Report: 91% Year-over-Year Surge in AI Activity Creates Growing Oversight Gap for Global Enterprises
Vizsla Copper Receives Letter of Support from Alaska Governor and Outlines 2026 Exploration Plans at the Palmer Project
